Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Product/R&D News
11/14/2025
NMPA Clears IND for GenSci's In-House Bispecific ADC GenSci140
11/13/2025
GenFleet Registers First Phase 3 Trial of KRAS G12D Inhibitor GFH375 i...
11/11/2025
Zydus Receives China NMPA Approval for Venlafaxine ER Capsules
11/11/2025
Glenmark Gains NMPA Approval for RYALTRIS®
11/11/2025
3SBio Presents Encouraging Phase 2 Results for SSGJ‑707 at SITC 2025
11/11/2025
China Approves CPEB's Pediatric CAR‑T Therapy for r/r B‑ALL
11/11/2025
Summit and Akeso Report Positive Phase III Results for Ivonescimab at ...
11/11/2025
Innovent and SanegeneBio Present Positive Phase 1 Data for siRNA Thera...
11/11/2025
Huahui to Present 48-Week Phase 2b Data of Libevitug at AASLD 2025
11/7/2025
Lepu to Present Promising Phase II Data of CD20 ADC MRG001 Plus Orelab...
11/7/2025
CARsgen Reports Positive Results for Allogeneic CAR-T Therapies CT0596...
11/7/2025
Sanofi's Cablivi Wins Approval in China as First Nanobody Therapy for ...
11/7/2025
Correctseq Reports World's First Gene-Editing Treatment for Hyperlipid...
11/6/2025
China Grants Conditional Approval for ACEA's COVID-19 Antiviral Olgotr...
11/6/2025
Novartis Wins China Approval for Two Pluvicto Indications
11/5/2025
AbbVie's CD20×CD3 Bispecific Epcoritamab Fails to Win China Approval
11/5/2025
Lumosa's Stroke Drug Achieves Phase IIb Success in China
11/5/2025
CDE Grants Breakthrough Therapy Designation to Ivonescimab for Triple-...
11/4/2025
Huadong Medicine Initiates Phase I Trial of CDH17-Targeting ADC HDM201...
11/4/2025
CStone Receives NMPA IND Approval for Phase II Trials of CS2009
11/4/2025
Abbisko Begins Phase II Trial of Oral PD-L1 Inhibitor ABSK043 in Combo...
11/4/2025
Genscript Secures NMPA IND Clearance for Second Bispecific ADC GenSci1...
10/31/2025
Lumosa's Stroke Drug Achieves Phase IIb Success in China
10/31/2025
Junshi's Toripalimab Becomes First Immunotherapy Approved for NPC in C...
10/31/2025
Sichuan Biokin Advances 11th ADC Candidate BL-M24D1 into Clinical Tria...
10/31/2025
NMPA Grants Conditional Approval for Lepu Biotech's Becotatug Vedotin
10/29/2025
NMPA Approves Huadong Pharma's Mifanertinib Maleate for EGFR-Mutant NS...
10/29/2025
Abbisko Presents Promising Preclinical Data on Novel CDK4/2 Inhibitor ...
10/28/2025
Metis TechBio to File China NDA for AI-Designed PBA Drug MTS-004
10/28/2025
Innovent's Mazdutide Tops Ozempic in Phase III Diabetes and Obesity Tr...
Page:
1
/
20
Total number of articles:
591
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit